In this mechanism, cisplatin induced miR-424 expression in bladder cancer cells in a HIF-1 α-dependent manner, and miR-424 conferred cisplatin resistance on bladder cancer cells in vitro and in vivo. Here, SETD2 is linked to urinary bladder carcinoma.